Skip to content

ProDigest

Active
Private limited companyfounded 2008active for 18 yearsTechnologiepark-Zwijnaarde 82, 9052 Gent, Belgium32 active companies are registered at this addressKBO/BCE: BE 0806.567.272
Summary

ProDigest has been active since 2008 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €5.2m and a net result of €32,740. Equity is growing by about 8.7% per year across the filed financial years. Its solvency ranks better than 65% of 271 sector peers (NACE 72, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).

Overview

Activity
Research and development on biotechnology
NACE 72101Other professional, scientific and technical activities NACE 74999
1 site
Size
≈ €7.3mturnover 2025, estimated
Staff
39.8 FTE
Equity
€5.2m
Profit
€32,740
Turnover estimated from the gross margin
Financial health
91 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
0.1%
Structure
Parent
Microbial Resource Management Technologies · 100%
Auditor: Deloitte Bedrijfsrevisoren/Réviseurs d’Entreprises2025 accounts 29 days early1 of 8 deeds summarised
Why 91raises risk1 of the last 3 latelowers riskFounded in 2008Liquidity: current ratio 3.07, cash €654,607Equity €5.2m (65.9% of total assets)Show the evidence

Checked score

Score 2025
91 / 100
Excellent
Probability in this band: under 0.55%
Financially better than 49% of its sector peers (NACE 72, small)
Financial strength · tick = 2024
Strong
Solvency 91=
equity 65.9% of total assets
Liquidity 50+5
short-term debt 27.4% · cash 8.4%
Profitability 69-2
return on assets 0.4%
Bankruptcy probability, 12 months
0.1% Very low
0%0.5%1.5%4%10%≥ 25%

About 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.1% (165 companies, NACE 72, small)
Last 24 months 11-2024: 0.4% 12-2024: 0.4%● unchanged vs 11-2024 01-2025: 0.4%● unchanged vs 12-2024 02-2025: 0.4%● unchanged vs 01-2025 03-2025: 0.4%● unchanged vs 02-2025 04-2025: 0.5%▲ +0.1 percentage points vs 03-2025 05-2025: 0.5%● unchanged vs 04-2025 06-2025: 0.6%▲ +0.1 percentage points vs 05-2025 07-2025: 0.7%▲ +0.1 percentage points vs 06-2025 08-2025: 0.9%▲ +0.2 percentage points vs 07-2025 09-2025: 1.0%▲ +0.1 percentage points vs 08-2025 10-2025: 1.4%▲ +0.4 percentage points vs 09-2025highest value 11-2025: 0.3%▼ -1.1 percentage points vs 10-2025 12-2025: 0.3%● unchanged vs 11-2025 01-2026: 0.3%● unchanged vs 12-2025 02-2026: 0.3%● unchanged vs 01-2026 03-2026: 0.3%● unchanged vs 02-2026 04-2026: 0.3%● unchanged vs 03-2026 05-2026: 0.3%● unchanged vs 04-2026 06-2026: 0.3%● unchanged vs 05-2026 07-2026: 0.3%● unchanged vs 06-2026 08-2026: 0.1%▼ -0.2 percentage points vs 07-2026lowest value 09-2026: 0.1%● unchanged vs 08-2026lowest value 10-2026: 0.1%● unchanged vs 09-2026lowest value
Credit of up to €460,000 on 30-day terms is acceptable
Liquidity ample (current ratio 3.07, compared with 2.66 in 2024, above the usual 1.5; short-term debt: 27.4% and cash: 8.4% of total assets), and 34.1% of the assets are financed with debt and provisions.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 72, small): better than 63% on solvency, 37% on liquidity, 59% on profitability and 37% on growth.

The bankruptcy probability was computed on 29-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Five signals.
lowers riskraises riskneutral
raises risk · 1 of the last 3 late
NBB · filings
lowers risk · Founded in 2008
Companies that have existed this long fail less often; how much that weighs depends on the rest of its profile.
KBO
lowers risk · Liquidity: current ratio 3.07, cash €654,607
NBB · annual accounts
lowers risk · Equity €5.2m (65.9% of total assets)
NBB · annual accounts
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 02-07-2026, 29 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
29 days early
2024
69 days late
2023
36 days early
2022
34 days early
2021
33 days early
2020
36 days early
2019
55 days late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 6 days before the deadline; the sector median (NACE 72) for financial year 2024 is 13 days before the deadline, and 32% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 28 June (4 of the last 5 filed years within 30 days of that day).
Companies Code · seven months
Where today falls in the filing period
30-10-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
Searched since 2021.
KBO publications · our coverage
  1. Annual accounts filedfinancial year 2025 · abbreviated…
  2. Annual accounts filedfinancial year 2024 · abbreviated…
  3. Reappointment: Deloitte Bedrijfsrevisoren BV (statutory auditor)Permanent representatives: Pieter-Jan Van Durme…

Financials · financial year 2025, abbreviated format

Turnover
≈ €7.3m
Estimated: probably between €4.9m and €12.0m
Total assets
€7.8m▲ 1.0%
2024 · €7.8m
Net result
€32,740▼ 70.5%
2024 · €110,989
Working capital
€4.4m▲ 14.4%
2024 · €3.9m
Trend over the years

2021 to 2025, 5 financial years 2018 to 2025, 8 financial years

The operating result falls in 2025; 2025 is 99% below 2024.

What the company sold each financial year and what was left of it. A loss stands below the zero line.

Operating result€0.001m 2025 Net result€0.03m 2025

Use the arrow keys on the chart for the figures per year.

Sector: the middle half of NACE 72, Scientific research and development: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30. Dashed line: the median. Available for Net result, Equity, Total assets, Working capital, Solvency, Current ratio, Return on assets (ROA), Staff (FTE).

Every figure with its change against the financial year before
favourable unfavourable
Line20182019202020212022202320242025
Operating result€0.03m--€0.4m€2.4m€2.8m▲ 15.6%€0.06m▼ 98.0%-€0.9m€0.09m€0.001m▼ 98.6%
Net result€0.009m--€0.4m€2.2mabove the sector's middle half€2.2mabove the sector's middle half▼ 1.2%€0.01mwithin the sector's middle half▼ 99.5%-€0.8mbelow the sector's middle half€0.1mwithin the sector's middle half€0.03mwithin the sector's middle half▼ 70.5%
Equity€2.1m-€1.5m▼ 28.2%€3.7mabove the sector's middle half▲ 145%€5.9mabove the sector's middle half▲ 58.5%€5.9mabove the sector's middle half▲ 0.2%€5.0mabove the sector's middle half▼ 14.4%€5.1mabove the sector's middle half▲ 2.2%€5.2mabove the sector's middle half▲ 0.6%
Total assets€4.8m-€4.5m▼ 7.8%€6.5mabove the sector's middle half▲ 45.2%€8.6mabove the sector's middle half▲ 32.2%€8.4mabove the sector's middle half▼ 2.1%€8.7mabove the sector's middle half▲ 4.2%€7.8mabove the sector's middle half▼ 11.2%€7.8mabove the sector's middle half▲ 1.0%
Debt€2.7m-€3.0m▲ 7.8%€2.8m▼ 5.8%€2.7m▼ 2.6%€2.5m▼ 6.9%€3.7m▲ 47.2%€2.6m▼ 29.3%€2.7m▲ 1.6%
Working capital€1.8m-€1.8m▼ 5.3%€3.9mabove the sector's middle half▲ 125%€5.9mabove the sector's middle half▲ 50.2%€5.3mabove the sector's middle half▼ 10.7%€4.2mabove the sector's middle half▼ 21.4%€3.9mabove the sector's middle half▼ 6.6%€4.4mabove the sector's middle half▲ 14.4%
Solvency43.3%-33.7%▼ 9.6pp57.0%within the sector's middle half▲ 23.3pp68.3%within the sector's middle half▲ 11.3pp69.9%within the sector's middle half▲ 1.6pp57.5%within the sector's middle half▼ 12.4pp66.1%within the sector's middle half▲ 8.7pp65.9%within the sector's middle half▼ 0.2pp
Current ratio1.82-1.79▼ 0.032.95within the sector's middle half▲ 1.164.03within the sector's middle half▲ 1.083.72within the sector's middle half▼ 0.312.46within the sector's middle half▼ 1.262.66within the sector's middle half▲ 0.193.07within the sector's middle half▲ 0.41
Return on assets (ROA)0.2%--9.3%▼ 9.5pp33.8%above the sector's middle half▲ 43.0pp25.2%above the sector's middle half▼ 8.5pp0.1%within the sector's middle half▼ 25.1pp-9.6%within the sector's middle half▼ 9.8pp1.4%within the sector's middle half▲ 11.1pp0.4%within the sector's middle half▼ 1.0pp
Staff (FTE)33.9-36.9above the sector's middle half38.6above the sector's middle half▲ 4.6%43.3above the sector's middle half▲ 12.2%45.8above the sector's middle half▲ 5.8%40.5above the sector's middle half▼ 11.6%39.8above the sector's middle half▼ 1.7%
above within below the middle half of NACE 72, Scientific research and development: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30.
Turnover and EBIT margin not published: the abbreviated format does not require them. The turnover shown is an estimate from the gross margin.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €7.8m
Fixed assets €1.2m ▼ 18.7%
Current assets €6.6m ▲ 5.8%
Equity and liabilities €7.8m
Equity €5.2m ▲ 0.6%
Debt €2.7m ▲ 1.6%
Debt's share of the balance-sheet total rises from 33.9% to 34.1%. Equity and debt are higher.
Key figures and ratios
2025 value · change against 2024
EBITDA
€570,521▼
2024 · €638,844
Cash flow
€601,924▼
2024 · €656,431
Quick ratio
2.88▲
2024 · 2.47
Debt to equity
0.52▲
2024 · 0.51
ROE
0.6%▼
2024 · 2.2%
Interest coverage
15.39▲
2024 · 8.88
Debt ≤ 1 year
€2.1m▼
2024 · €2.3m
Debt > 1 year
€0▼
2024 · €141,209
Staff costs
€3.6m▲
2024 · €3.6m
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.

Peer companies

Historical observation

Of the 6,049 companies that looked in July 2024 the way this one looks now, 0.4% went bankrupt within 24 months and 95.9% are still going.

  • Small
  • 10 to 20 years old
  • solvency 30% or more
  • a profit under 5% of the balance sheet
0.4% went bankrupt
3.6% stopped otherwise
95.9% still going

For this company itself Checked computes a bankruptcy probability of 0.1% over twelve months; the group does not contradict it.

How reliable is this rule?

Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,445 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.

The companies in ten equal groups, from lowest to highest expected share.
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 3.0% 3.1%
10 5.6% 6.2%

The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74.5% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.

An observation about 6,049 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.

Annual accounts
Filed annual accounts As filed with the NBB · 2025 against 2024 · 61 lines
Balance sheet Code20242025
Assets
Total assets20/58€7.8m€7.8m▲
Fixed assets21/28€1.5m€1.2m▼
Intangible fixed assets21€0.02m€0.06m▲
Tangible fixed assets22/27€1.5m€1.1m▼
Plant, machinery and equipment23€1.4m€1.0m▼
Furniture and vehicles24€0.06m€0.1m▲
Assets under construction and advance payments27€0-
Financial fixed assets28€0.05m€0.05m▼
Current assets29/58€6.2m€6.6m▲
Amounts receivable after more than one year29€1.6m€1.9m▲
Trade receivables290€0.08m€0.08m=
Other amounts receivable291€1.5m€1.8m▲
Stocks and contracts in progress3€0.4m€0.4m▼
Stocks30/36€0.4m€0.4m▼
Contracts in progress37€0-
Amounts receivable within one year40/41€3.4m€3.4m▼
Trade receivables40€3.0m€2.9m▼
Other amounts receivable41€0.4m€0.5m▲
Current investments50/53€0.1m€0▼
Cash at bank and in hand54/58€0.5m€0.7m▲
Deferred charges and accrued income490/1€0.2m€0.3m▲
Equity and liabilities
Total equity and liabilities10/49€7.8m€7.8m▲
Equity10/15€5.1m€5.2m▲
Contributions10/11€0.2m€0.2m=
Reserves13€1.1m€1.1m=
Distributable reserves133€1.1m€1.1m=
Profit (loss) carried forward14€3.8m€3.9m▲
Amounts payable17/49€2.6m€2.7m▲
Amounts payable after more than one year17€0.1m€0▼
Financial debts170/4€0.1m€0▼
Amounts payable within one year42/48€2.3m€2.1m▼
Current portion of amounts payable after more than one year42€0.6m€0.1m▼
Financial debts43€71€0.005m▲
Credit institutions430/8€71€0.005m▲
Trade debts44€0.7m€0.6m▼
Suppliers440/4€0.7m€0.6m▼
Advances received on contracts in progress46€0.6m€1.0m▲
Taxes, remuneration and social security45€0.5m€0.5m▼
Taxes450/3€0.02m€0.004m▼
Remuneration and social security454/9€0.5m€0.5m▼
Other amounts payable47/48€0.07m€0▼
Accrued charges and deferred income492/3€0.1m€0.5m▲
Income statement Code20242025
Non-recurring operating income76A€0€40▲
Remuneration, social security and pensions62€3.6m€3.6m▲
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€0.5m€0.6m▲
Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4€0.01m€0.01m▼
Other operating charges640/8€0.01m€0.009m▼
Gross operating margin9900€4.2m€4.2m▼
Operating profit (loss)9901€0.09m€0.001m▼
Financial income75/76B€0.1m€0.1m▼
Recurring financial income75€0.1m€0.1m▼
Financial charges65/66B€0.1m€0.07m▼
Recurring financial charges65€0.07m€0.04m▼
Non-recurring financial charges66B€0.04m€0.03m▼
Profit (loss) for the period before taxes9903€0.1m€0.03m▼
Income taxes67/77€0-
Profit (loss) for the period9904€0.1m€0.03m▼
Profit (loss) for the period to be appropriated9905€0.1m€0.03m▼
Appropriation of the result
Profit (loss) to be appropriated9906€3.8m€3.9m▲
Profit (loss) brought forward from the previous period14P€3.7m€3.8m▲
Social balance sheet
Average headcount (FTE)908740.539.8▼

The notes to these accounts (21 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Line20182019202020212022202320242025Change
Non-recurring operating income76A---€0.006m€0.02m€0.01m€0€40-
Remuneration, social security and pensions62-€3.0m-€2.8m€3.3m€3.9m€3.6m€3.6m▲ 1.5%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€0.3m€0.3m€0.2m€0.2m€0.3m€0.5m€0.5m€0.6m▲ 4.4%
Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4------€0.01m€0.01m▼ 21.0%
Other operating charges640/8-€0.04m-€0.006m€0.01m€0.007m€0.01m€0.009m▼ 14.7%
Non-recurring operating charges66A-€0.03m-€0.02m€0.01m€0---
Gross operating margin9900€3.0m€2.9m€5.1m€5.9m€3.7m€3.5m€4.2m€4.2m▼ 0.4%
Operating profit (loss)9901€0.03m-€0.4m€2.4m€2.8m€0.06m-€0.9m€0.09m€0.001m▼ 98.6%
Financial income75/76B-€0.006m-€0.05m€0.03m€0.1m€0.1m€0.1m▼ 20.2%
Recurring financial income75€0.006m€0.006m€0.03m€0.05m€0.03m€0.1m€0.1m€0.1m▼ 20.2%
Financial charges65/66B-€0.04m-€0.02m€0.07m€0.09m€0.1m€0.07m▼ 35.8%
Recurring financial charges65€0.02m€0.04m€0.05m€0.02m€0.04m€0.09m€0.07m€0.04m▼ 48.5%
Non-recurring financial charges66B---€0.006m€0.03m€409€0.04m€0.03m▼ 12.6%
Profit (loss) for the period before taxes9903€0.01m-€0.4m€2.4m€2.8m€0.01m-€0.8m€0.1m€0.03m▼ 70.5%
Income taxes67/77€0.004m€0€0.2m€0.7m€0.003m€0.001m€0--
Profit (loss) for the period9904€0.009m-€0.4m€2.2m€2.2m€0.01m-€0.8m€0.1m€0.03m▼ 70.5%
Transfer from tax-exempt reserves789-€0-------
Transfer to tax-exempt reserves689---€0-----
Profit (loss) for the period to be appropriated9905€0.2m-€2.1m€2.2m€0.01m-€0.8m€0.1m€0.03m▼ 70.5%
Line20182019202020212022202320242025Change
Assets
Total assets20/58€4.8m€4.5m€6.5m€8.6m€8.4m€8.7m€7.8m€7.8m▲ 1.0%
Fixed assets21/28€0.7m€0.5m€0.5m€0.7m€1.2m€1.7m€1.5m€1.2m▼ 18.7%
Intangible fixed assets21€0.002m€0.001m€0.001m€0-€0.02m€0.02m€0.06m▲ 146%
Tangible fixed assets22/27€0.7m€0.5m€0.5m€0.7m€1.2m€1.7m€1.5m€1.1m▼ 22.1%
Plant, machinery and equipment23-€0.4m-€0.6m€1.1m€1.6m€1.4m€1.0m▼ 25.6%
Furniture and vehicles24-€0.03m-€0.09m€0.1m€0.08m€0.06m€0.1m▲ 55.2%
Other tangible fixed assets26-€0.01m-€0.01m€0----
Assets under construction and advance payments27-----€0.02m€0--
Financial fixed assets28€0.004m€0.001m€0.001m€0.001m€0.001m€0.001m€0.05m€0.05m▼ 1.9%
Current assets29/58€4.1m€4.0m€6.0m€7.9m€7.2m€7.0m€6.2m€6.6m▲ 5.8%
Amounts receivable after more than one year29-€0.2m-€0.1m€0.1m€1.5m€1.6m€1.9m▲ 19.5%
Trade receivables290------€0.08m€0.08m=
Other amounts receivable291-€0.2m-€0.1m€0.1m€1.5m€1.5m€1.8m▲ 20.4%
Stocks and contracts in progress3€0.1m€0.3m€0.2m€0.4m€0.3m€0.5m€0.4m€0.4m▼ 11.3%
Stocks30/36-€0.3m-€0.4m€0.3m€0.4m€0.4m€0.4m▼ 11.3%
Contracts in progress37-----€0.1m€0--
Amounts receivable within one year40/41€2.9m€2.7m€3.8m€4.0m€4.4m€4.2m€3.4m€3.4m▼ 0.6%
Trade receivables40-€2.2m-€3.4m€3.5m€3.5m€3.0m€2.9m▼ 3.8%
Other amounts receivable41-€0.5m-€0.6m€0.9m€0.6m€0.4m€0.5m▲ 21.9%
Current investments50/53€0.1m€0.1m€0.1m€0.1m€0.1m€0.1m€0.1m€0▼ 100%
Cash at bank and in hand54/58€1.0m€0.7m€1.8m€3.2m€2.2m€0.4m€0.5m€0.7m▲ 43.4%
Deferred charges and accrued income490/1-€0.05m-€0.01m€0.1m€0.2m€0.2m€0.3m▲ 17.7%
Equity and liabilities
Total equity and liabilities10/49€4.8m€4.5m€6.5m€8.6m€8.4m€8.7m€7.8m€7.8m▲ 1.0%
Equity10/15€2.1m€1.5m€3.7m€5.9m€5.9m€5.0m€5.1m€5.2m▲ 0.6%
Contributions10/11€0.3m€0.2m-€0.2m€0.2m€0.2m€0.2m€0.2m=
Capital10-€0.2m-------
Issued capital100-€0.2m-------
Reserves13€1.2m€1.0m€1.1m€1.1m€1.1m€1.1m€1.1m€1.1m=
Legal reserve130-€0.02m-------
Tax-exempt reserves132-€0.07m-------
Distributable reserves133-€0.9m-€1.1m€1.1m€1.1m€1.1m€1.1m=
Profit (loss) carried forward14€0.6m€0.3m€2.4m€4.5m€4.6m€3.7m€3.8m€3.9m▲ 0.9%
Amounts payable17/49€2.7m€3.0m€2.8m€2.7m€2.5m€3.7m€2.6m€2.7m▲ 1.6%
Amounts payable after more than one year17€0.2m€0.1m€0.2m€0.3m€0.08m€0.5m€0.1m€0▼ 100%
Financial debts170/4-€0.1m-€0.3m€0.08m€0.5m€0.1m€0▼ 100%
Amounts payable within one year42/48€2.3m€2.2m€2.0m€2.0m€1.9m€2.8m€2.3m€2.1m▼ 8.4%
Current portion of amounts payable after more than one year42-€0.2m-€0.2m€0.5m€0.6m€0.6m€0.1m▼ 75.2%
Financial debts43-€0.2m----€71€0.005m▲ 73×
Credit institutions430/8-€0.2m----€71€0.005m▲ 73×
Trade debts44€1.4m€0.8m€0.8m€0.7m€0.7m€0.7m€0.7m€0.6m▼ 14.8%
Suppliers440/4-€0.8m-€0.7m€0.7m€0.7m€0.7m€0.6m▼ 14.8%
Advances received on contracts in progress46-€0.4m-€0.4m€0.3m€0.7m€0.6m€1.0m▲ 76.7%
Taxes, remuneration and social security45-€0.3m-€0.7m€0.4m€0.4m€0.5m€0.5m▼ 6.1%
Taxes450/3-€0.03m-€0.3m€0.06m€0.003m€0.02m€0.004m▼ 80.4%
Remuneration and social security454/9-€0.3m-€0.3m€0.4m€0.4m€0.5m€0.5m▼ 3.0%
Other amounts payable47/48-€0.2m-€0.02m€0.02m€0.4m€0.07m€0▼ 100%
Accrued charges and deferred income492/3-€0.6m-€0.4m€0.5m€0.4m€0.1m€0.5m▲ 269%
Line20182019202020212022202320242025Change
Profit (loss) for the period9904€0.009m-€0.4m€2.2m€2.2m€0.01m-€0.8m€0.1m€0.03m▼ 70.5%
+ Depreciation and write-downs630€0.3m€0.3m€0.2m€0.2m€0.3m€0.5m€0.5m€0.6m▲ 4.4%
Operating cash flow (approximation)€0.3m-€0.1m€2.4m€2.4m€0.4m-€0.4m€0.7m€0.6m▼ 8.3%
Investment in fixed assets (approximation)--€0.02m-€0.2m-€0.4m-€0.8m-€1.1m-€0.3m-€0.3m▲ 16.1%
Change in cash--€0.3m€1.1m€1.5m-€1.0m-€1.8m€0.04m€0.2m▲ 361%

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Download as CSV

Latest 10 of 17 filings with the National Bank
Financial year Type Filed Reference
31-12-2025 abbreviated format 02-07-2026 2026-00242358
31-12-2024 abbreviated format 08-10-2025 2025-00539276
31-12-2023 abbreviated format 25-06-2024 2024-00198189
31-12-2022 abbreviated format 27-06-2023 2023-00174985
31-12-2021 abbreviated format 28-06-2022 2022-20140236
31-12-2020 abbreviated format 25-06-2021 2021-25400560
31-12-2019 abbreviated format 24-09-2020 2020-55500336
31-12-2018 abbreviated format 06-06-2019 2019-16600342
31-12-2017 abbreviated format 28-06-2018 2018-25900218
31-12-2016 abbreviated format 22-06-2017 2017-20200367

Show all 17 filings

Similar companies · same sector, comparable size

Of the 760 active companies whose main activity is research and development on biotechnology (NACE 72101), figures are known for 484. 197 are within a factor 10 of this equity. These 5 are the closest to it. See the whole sector

Subsidies and aid

Flemish government

2022 to 2025 · 18 entries · €1.3m awarded · €718,869 paid
Year Entries AwardedPaid
2025 7 €519,160€184,264
2024 5 €2,300€273,331
2023 4 €399,116€127,664
2022 2 €334,003€133,610
Schemes
4 entries · €820,764 · €347,000 paid · Fonds voor Innoveren en Ondernemen
4 entries · €329,769 · €329,769 paid · Fonds voor Innoveren en Ondernemen
4 entries · €87,873 · €34,000 paid · Fonds voor Innoveren en Ondernemen
4 entries · €9,969 · €1,896 paid · Fonds voor Innoveren en Ondernemen
1 entry · €5,304 · €5,304 paid · Departement Werk en Sociale Economie
Show 1 more
1 entry · €900 · €900 paid · Vlaams Agentschap voor Internationaal Ondernemen

European research

7 projects · 1 as coordinator · €2.7m EU contribution
Programmes
5 entries · €2.0m
2 entries · €719,664
Projects
Use of Microorganisms for Carotenoids Delivery: Next Generation of Probiotics for Cardiovascular Disease
Seventh Framework Programme · coordinator · 01-12-2013 to 31-12-2015 · €648,771 · CARODEL
Satiety Innovation
Seventh Framework Programme · participant · 01-01-2012 to 31-12-2016 · €463,727 · SATIN
New siRNA Nanotherapy for Inflammatory Bowel Diseases, targeting Janus kinases
Horizon 2020 · participant · 01-01-2017 to 30-09-2021 · €463,344 · NEW DEAL
Dietary Fibers supporting Gut and Immune Function - From polysaccharide compound to health claim
Seventh Framework Programme · participant · 01-01-2012 to 30-06-2016 · €417,739 · FIBEBIOTICS
Deciphering the fungus-host-microbiota interplay to improve the management of fungal infections
Horizon 2020 · participant · 01-01-2019 to 30-06-2023 · €256,320 · FunHoMic
Show 2 more projects
Beneficial effects of dietary bioactive peptides and polyphenols on cardiovascular health in humans
Seventh Framework Programme · participant · 01-10-2012 to 30-09-2016 · €221,512 · BACCHUS
Biopolymer Based FOOd Delivery Systems
Seventh Framework Programme · participant · 01-02-2014 to 31-01-2018 · €209,660 · BIBAFOODS

Public contracts

4 awards · 2024 to 2025
Dostawa symulatora układu pokarmowego człowieka
buyer: Instytut Genetyki Człowieka Polskiej Akademii NaukLaboratory, optical and precision equipmentawarded 28-11-2025€197,3001 tenderTED 810103-2025
Beschaffung eines komplexen Systems zur Simulierung von Verdauungs- und Fermentationsprozessen im Magen-Darmtrakt von Mensch und Tier
buyer: Veterinärmedizinische Universität WienMedical equipment and pharmaceuticalsawarded 13-01-2025€265,783TED 39398-2025
Intestinal Modelling System: Qualification
buyer: Lunds universitetLaboratory, optical and precision equipmentawarded 03-03-20241 tenderTED 194666-2024
Intestinal Modelling System: Requirements
buyer: Lunds universitetLaboratory, optical and precision equipmentawarded 03-03-20241 tenderTED 194666-2024

Source: TED (Tenders Electronic Daily), Publications Office of the European Union. Values as the buyer published them; for a framework agreement, a ceiling.

Directors

Directors

Statutory auditor 1

Deloitte Bedrijfsrevisoren/Réviseurs d’Entreprises
Statutory auditor · since 25-09-2025 · permanent representative: Pieter-Jan Van Durme
Current
Derived from published Gazette deeds. The KBO keeps the official list of office holders; we do not read it, so the two can differ. See the directors and other office holders in the KBO →

Mandate history

1 person since 2025, 1 in office
Show
  • Statutory auditor
Mandates per person, with start and end dates
Name Functions and periods
Deloitte Bedrijfsrevisoren/Réviseurs d’Entreprises
  • Statutory auditor, from 25-09-2025 to date
See the board, name and registered office on a given date →

Owners and capital

Owners

1 owner

Chain of control

  1. Microbial Resource Management Technologies 100%
  2. ProDigest

Highest known parent: Microbial Resource Management Technologies. The sources do not say who stands above it.

Sources: the companies' annual accounts, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.

Group and network

Connections & network

Depth

The network starts from this company’s shareholders. What else they own or run appears here as nodes.

This company Company Director Shareholding +N: links not shown yet Click a node to look further, drag to arrange, zoom with the mouse wheel.

History

ProDigest was incorporated on 24 September 2008.1 Total assets rose from €4.8m in 2018 to €7.8m in 2025 and headcount from 33.9 to 39.8 full-time equivalents.2

  1. 1KBO register
  2. 2National Bank, annual accounts 2018 and 2025

Acts, filings and financial milestones

Next filing, financial year 2026, expected by 31-07-2027
2026
02-07
NBB filing Annual accounts filed
financial year 2025 · abbreviated format
2025
08-10
NBB filing Annual accounts filed
financial year 2024 · abbreviated format · 69 days late
25-09
Gazette deed Reappointment: Deloitte Bedrijfsrevisoren BV (statutory auditor)
Permanent representatives: Pieter-Jan Van Durme and Massimo Marzorati · Power of attorney9 facts ▸
  • General meeting, 18-03-2025
  • Auditor reappointment, Deloitte Bedrijfsrevisoren BV (statutory auditor)
  • Permanent representative, Pieter-Jan Van Durme
  • Power of attorney, Moore Finance & Tax BV
  • Power of attorney, Tanja De Naeyer
  • Power of attorney, Dominique Jaminet
  • Power of attorney, Valira Baleci
  • Power of attorney, Kaat Willems
  • Permanent representative, Massimo Marzorati
2024
31-12
Financial Back to profitnet €110,989
Net result €110,989 after one loss-making year.
25-06
NBB filing Annual accounts filed
financial year 2023 · abbreviated format
2023
31-12
Financial Weakest financial yearnet -€842,708
Net result drops to -€842,708, the lowest in the series; recovery starts the following year.
27-06
NBB filing Annual accounts filed
financial year 2022 · abbreviated format
2022
28-06
NBB filing Annual accounts filed
financial year 2021 · abbreviated format
2021
31-12
Financial Equity above €5mequity €5.9m ▲58.5%
2 profitable years in a row build equity to €5.9m.
25-06
NBB filing Annual accounts filed
financial year 2020 · abbreviated format
2020
31-12
Financial Back to profitnet €2.2m
Net result €2.2m after one loss-making year.
31-12
Financial Equity above €2mequity €3.7m ▲145%
Equity rises from €1.5m to €3.7m.
Show earlier events
24-09
NBB filing Annual accounts filed
financial year 2019 · abbreviated format · 55 days late
2019
06-06
NBB filing Annual accounts filed
financial year 2018 · abbreviated format
2018
28-06
NBB filing Annual accounts filed
financial year 2017 · abbreviated format
2017
22-06
NBB filing Annual accounts filed
financial year 2016 · abbreviated format
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.Of the 17 annual accounts filed, the latest 10 are here; all 17 are under Financials.
1 of 8 deeds read
About the unread acts

Of the 8 Belgian Official Gazette deeds we know for this company, 1 has been read. The other 7 have not been read yet: what they contain is neither established nor disproved here.

Have them read with priority Sign in to place this company at the front of the reading queue.

Register details

Identification
Legal formPrivate limited company
Founded24-09-2008
Financial year end31-12
Activities, NACEBEL 2025
72101Research and development on biotechnology
74999Other professional, scientific and technical activities
72109Other research and development on natural sciences
E-invoicing
Reachable via Peppol
Peppol ID 0208:0806567272
Also 9925:BE0806567272
Registered 08-12-2025

If you follow this company, Checked tells you the day it leaves the Peppol register.

Register as of 29 October 2026 · Peppol Directory

Scores and ratios are computed by Checked and are not a credit decision.

Recognitions · licences · registrations

Legal Entity Identifier

875500ZXCIZI8R5SBQ56
live in the LEI register

Environmental permits: No permit applications found in Flanders. Brussels and Wallonia do not publish the applicant.

Sites & property

Location & real-estate footprint
Registered office, Gent · 1 establishment unit since 2008
registered office establishment approximate The establishment unit on the map
Ground area
1.5 ha
Building footprint
9,047 m²
Building volume
114,315 m³
2 parcels, Flanders · tallest building 23.8 m. Linked by address, not a title deed.
32 companies at this address See who is registered here
1 establishment unit
Technologiepark-Zwijnaarde 4, 9052 Gent
Research and development on biotechnology
since 2008unit no. 2.174.580.345
2 parcels
Flanders 2 (100%)
Cadastral parcel Region Area Buildings Height / floors
44082B0137/00V000 Flanders 1.3 ha 1 · 7,125 m² 23.8 m · 5
44082B0143/00K000 Flanders 2,851 m² 1 · 1,922 m² 6.3 m · 2
How the parcels are linked
Good to know
Both parcels match the address exactly.